Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE

Trial Profile

Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Idelalisib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Mediastinal disorders
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Jan 2019 This study has been discontinued in Spain.
    • 07 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top